Literature DB >> 15671438

Hepcidin in iron overload disorders.

George Papanikolaou1, Michalis Tzilianos, John I Christakis, Dionisios Bogdanos, Konstantina Tsimirika, Julie MacFarlane, Y Paul Goldberg, Nikos Sakellaropoulos, Tomas Ganz, Elizabeta Nemeth.   

Abstract

Hepcidin is the principal regulator of iron absorption in humans. The peptide inhibits cellular iron efflux by binding to the iron export channel ferroportin and inducing its internalization and degradation. Either hepcidin deficiency or alterations in its target, ferroportin, would be expected to result in dysregulated iron absorption, tissue maldistribution of iron, and iron overload. Indeed, hepcidin deficiency has been reported in hereditary hemochromatosis and attributed to mutations in HFE, transferrin receptor 2, hemojuvelin, and the hepcidin gene itself. We measured urinary hepcidin in patients with other genetic causes of iron overload. Hepcidin was found to be suppressed in patients with thalassemia syndromes and congenital dyserythropoietic anemia type 1 and was undetectable in patients with juvenile hemochromatosis with HAMP mutations. Of interest, urine hepcidin levels were significantly elevated in 2 patients with hemochromatosis type 4. These findings extend the spectrum of iron disorders with hepcidin deficiency and underscore the critical importance of the hepcidin-ferroportin interaction in iron homeostasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15671438      PMCID: PMC1895089          DOI: 10.1182/blood-2004-12-4844

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

Review 1.  Disorders of iron metabolism.

Authors:  N C Andrews
Journal:  N Engl J Med       Date:  1999-12-23       Impact factor: 91.245

2.  Ferroportin mutation in autosomal dominant hemochromatosis: loss of function, gain in understanding.

Authors:  R E Fleming; W S Sly
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

3.  Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice.

Authors:  G Nicolas; M Bennoun; I Devaux; C Beaumont; B Grandchamp; A Kahn; S Vaulont
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

4.  Genetic hyperferritinaemia and reticuloendothelial iron overload associated with a three base pair deletion in the coding region of the ferroportin gene (SLC11A3).

Authors:  Mario Cazzola; Laura Cremonesi; Maria Papaioannou; Nadia Soriani; Anna Kioumi; Anastasia Charalambidou; Rita Paroni; Katerina Romtsou; Sonia Levi; Maurizio Ferrari; Paolo Arosio; John Christakis
Journal:  Br J Haematol       Date:  2002-11       Impact factor: 6.998

5.  The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation.

Authors:  Gaël Nicolas; Caroline Chauvet; Lydie Viatte; Jean Louis Danan; Xavier Bigard; Isabelle Devaux; Carole Beaumont; Axel Kahn; Sophie Vaulont
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

6.  Severe iron deficiency anemia in transgenic mice expressing liver hepcidin.

Authors:  Gaël Nicolas; Myriam Bennoun; Arlette Porteu; Sandrine Mativet; Carole Beaumont; Bernard Grandchamp; Mario Sirito; Michèle Sawadogo; Axel Kahn; Sophie Vaulont
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-02       Impact factor: 11.205

7.  Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis.

Authors:  Kim R Bridle; David M Frazer; Sarah J Wilkins; Jeanette L Dixon; David M Purdie; Darrell H G Crawford; V Nathan Subramaniam; Lawrie W Powell; Gregory J Anderson; Grant A Ramm
Journal:  Lancet       Date:  2003-02-22       Impact factor: 79.321

8.  Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease.

Authors:  David A Weinstein; Cindy N Roy; Mark D Fleming; Massimo F Loda; Joseph I Wolfsdorf; Nancy C Andrews
Journal:  Blood       Date:  2002-06-28       Impact factor: 22.113

9.  Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis.

Authors:  Antonella Roetto; George Papanikolaou; Marianna Politou; Federica Alberti; Domenico Girelli; John Christakis; Dimitris Loukopoulos; Clara Camaschella
Journal:  Nat Genet       Date:  2002-12-09       Impact factor: 38.330

10.  Hepcidin is decreased in TFR2 hemochromatosis.

Authors:  Elizabeta Nemeth; Antonella Roetto; Giovanni Garozzo; Tomas Ganz; Clara Camaschella
Journal:  Blood       Date:  2004-10-14       Impact factor: 22.113

View more
  121 in total

1.  Measurement of serum hepcidin-25 levels as a potential test for diagnosing hemochromatosis and related disorders.

Authors:  Yoshibumi Kaneko; Hiroaki Miyajima; Alberto Piperno; Naohisa Tomosugi; Hisao Hayashi; Natsuko Morotomi; Ken-ichi Tsuchida; Takaaki Ikeda; Akihisa Ishikawa; Yusuke Ota; Shinya Wakusawa; Kentaro Yoshioka; Satoshi Kono; Sara Pelucchi; Ai Hattori; Yasuaki Tatsumi; Toshihide Okada; Masakazu Yamagishi
Journal:  J Gastroenterol       Date:  2010-06-09       Impact factor: 7.527

Review 2.  Hepcidin and iron homeostasis.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Biochim Biophys Acta       Date:  2012-01-26

Review 3.  Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia.

Authors:  Sara Gardenghi; Robert W Grady; Stefano Rivella
Journal:  Hematol Oncol Clin North Am       Date:  2010-10-15       Impact factor: 3.722

4.  Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia.

Authors:  Léon Kautz; Grace Jung; Xin Du; Victoria Gabayan; Justin Chapman; Marc Nasoff; Elizabeta Nemeth; Tomas Ganz
Journal:  Blood       Date:  2015-08-14       Impact factor: 22.113

5.  TLR4-dependent hepcidin expression by myeloid cells in response to bacterial pathogens.

Authors:  Carole Peyssonnaux; Annelies S Zinkernagel; Vivekanand Datta; Xavier Lauth; Randall S Johnson; Victor Nizet
Journal:  Blood       Date:  2006-01-03       Impact factor: 22.113

Review 6.  Survival of the fittest: in vivo selection and stem cell gene therapy.

Authors:  Tobias Neff; Brian C Beard; Hans-Peter Kiem
Journal:  Blood       Date:  2005-11-03       Impact factor: 22.113

7.  DMT1 mutation: response of anemia to darbepoetin administration and implications for iron homeostasis.

Authors:  Dagmar Pospisilova; Martha P Mims; Elizabeta Nemeth; Tomas Ganz; Josef T Prchal
Journal:  Blood       Date:  2006-07-01       Impact factor: 22.113

8.  Of mice and men: the iron age.

Authors:  Sophie Vaulont; Dan-Qing Lou; Lydie Viatte; Axel Kahn
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

9.  An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia.

Authors:  Paul J Schmidt; Iva Toudjarska; Anoop K Sendamarai; Tim Racie; Stuart Milstein; Brian R Bettencourt; Julia Hettinger; David Bumcrot; Mark D Fleming
Journal:  Blood       Date:  2012-12-06       Impact factor: 22.113

Review 10.  Regulation of iron absorption in hemoglobinopathies.

Authors:  Gideon Rechavi; Stefano Rivella
Journal:  Curr Mol Med       Date:  2008-11       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.